Abstract:The study focuses on the design of novel Isatin derivatives as BCR‐ABL tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia cell line (k562) using 3D‐QSAR, ADMET, molecular docking, MM‐GBSA, and molecular dynamics studies. These findings hold promise for the future development of potent BCR‐ABL tyrosine kinase inhibitors. Inserting Isatin (1H indole 2,3‐dione) stands out as an exceptionally captivating element in the realm of drug design and development. Hence, there has been a notable focus in numerous anticancer studies on investigating the potential of various derivatives of Isatin (1H indole 2,3‐dione), including imines, hydrazones, thiosemicarbazones, and other compounds. Therefore, to develop new compounds with anticipated high activity, a novel series of 40 Isatin derivatives have undergone 3D‐QSAR studies as potent anticancer agents against the leukemia cell line (K562). This approach has been pursued due to the significant importance placed on exploring the potential of these derivatives. Through the analysis of graphical contour maps, the generated models yielded favorable statistical outcomes and provided valuable insights into the structural elements that exert a significant influence on the activity. Furthermore, both CoMFA and CoMSIA models have shown suitable reliabilities (q2 = 0.689, 0.772, respectively) and predictive abilities (r2pred = 0.780, 0.892, respectively). As a result, the design of five new compounds (T1–T5) based on the Isatin moiety, which exhibited remarkable inhibitory activity, has successfully been accomplished. Accordingly, molecular docking and molecular dynamics (MD) simulations of 100 ns have been utilized to examine the interaction mechanism and conformational changes of the newly designed compounds at the binding site of BCR‐ABL tyrosine kinase. MD simulation revealed that both compounds T1 and T2 formed stable complexes with BCR‐ABL. Additionally, the assessment of the in‐silico pharmacokinetic parameters indicates favorable ADMET properties. These findings hold promise for the future development of potent BCR‐ABL tyrosine kinase inhibitors.

Design, Synthesis, and in Vitro Antiproliferative Activity of Novel Dasatinib Derivatives.

Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.

Design, synthesis and antiproliferative activity of 2-acetamidothiazole-5-carboxamide derivatives.

Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells.

Part-1: Design, synthesis and biological evaluation of novel bromo-pyrimidine analogs as tyrosine kinase inhibitors

Synthesis and Biological Activities of 2-Amino-thiazole-5-carboxylic Acid Phenylamide Derivatives.

Design, Synthesis, and in Vitro Antitumor Evaluation of Novel Phenylaminopyrimidine Derivatives.

Design, synthesis and anti-tumor activity of novel 5-amino-2-(benzylthio) thia-zole-4-carboxamide derivatives

Design and Synthesis of New Imatinib Analogs Containing Thiazolyl Moiety

Design, synthesis and antitumor evaluation of 3-chloro-4 - (pyridin-2-ylmethoxy) aniline derivatives as BCR-ABL kinase

Design, Synthesis, and Anticancer Activity of Novel Methoxycyclohexyl Nicotinamides

Design,synthesis and in vitro activity study of a novel Bcl-2 protein inhibitors

Design, synthesis and biological evaluation of 2-amino-N-(2-aminophenyl)thiazole-5-carboxamide derivatives as novel Bcr-Abl and histone deacetylase dual inhibitors

Discovery of a New Isatin Scaffold for BCR‐ABL Tyrosine Kinase Inhibitors Using a Comprehensive Computational Approach

Design, Synthesis and Biological Activities of Nilotinib Derivates As Antitumor Agents.

Design, Synthesis and Antitumor Activity of 6,7-Disubstituted-4-(heteroarylamino)quinoline-3-carbonitrile Derivatives

Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors.

Design, Synthesis and Biological Evaluation of Novel Dithiocarbamate-Substituted Diphenylaminopyrimidine Derivatives As BTK Inhibitors

Design, synthesis and biological evaluation of novel 1,5-disubstituted isatin derivatives as antitumor agents

Design, Synthesis, and Antitumor Activity of Benzimidazole Derivatives As CDK4/6 Inhibitors

Design, Synthesis and Antitumor Evaluation of a New Series of N-substituted-thiourea Derivatives